Does Semax help with stroke recovery? Grade D evidence

What the studies show

The basis of the Russian registration. Not reproduced in trials meeting international reporting standards.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

1
Searches of PubMed and trial registries for Semax human trials outside Russia.LYO literature search, September 2026No randomised trials meeting international reporting standards were identified.

In context

Semax is a seven-amino-acid peptide derived from ACTH, developed in Russia in the 1980s and registered there for stroke and cognitive indications. It is not approved in the EU, US or UK. The human literature is almost entirely Russian-language, largely uncontrolled or poorly reported by international standards, and has not been replicated by independent groups — which is why the cognitive and stroke claims sit at grade D despite the registration.

Semax is not approved (outside russia). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Semax proven to help with stroke recovery?

No. There is no human evidence for it (Russian trials, not independently replicated); the claim rests on animal or cell studies and LYO grades it D.

What studies are behind the grade?

The basis of the Russian registration. Not reproduced in trials meeting international reporting standards.

Is Semax approved for this?

No. Semax is not approved (outside Russia); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Semax

DCognitive performanceRussian-language, mostly uncontrolled
DAnxiety / stressNone controlled internationally
DSafety in humansadverseNo systematic international data

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →